PAN Dengke, Second-Grade Research Fellow, Doctoral Supervisor; Director of the Sichuan Provincial Key Laboratory of Xenotransplantation and Regeneration; Specially Research Fellow at West China Hospital, Sichuan University. Vice Chair of the Xenotransplantation Subgroup, Organ Transplantation Branch, Chinese Medical Association. Founder and Chairman of Clonorgan Biotechnology Co., Ltd.

In 2005, produced China's first somatic cell-cloned pig. In 2010, produced China's first GTKO gene knockout pig. In 2018, founded Clonorgan Biotechnology, where he established more than 10 genetically edited donor pig lines and constructed ultra-clean facilities for breeding medical-grade designated pathogen-free (DPF) pigs for clinical use.

Collaborated on the world's first subclinical study of genetically edited pig liver and lung transplantation into humans. Collaborated on Asia's first clinical study of genetically edited pig kidney transplantation into a patient; the pig kidney functioned for 261 days in the patient, representing the second-longest survival record for a pig kidney in a human recipient internationally. Collaborated on the world's first successful extracorporeal perfusion therapy for liver failure using a genetically edited pig liver; following 66 hours of continuous treatment, the patient's condition was favorable with significant improvement in major liver function indicators, providing a novel strategy for future clinical treatment of end-stage liver disease and bridging therapy prior to liver transplantation.

Recipient of two Second Prizes of the National Science and Technology Progress Award and one Second Prize of the Da Bei Nong Science and Technology Award. Holder of 10 authorized invention patents. Author of more than 120 peer-reviewed publications in journals including Nature Medicine, Proceedings of the National Academy of Sciences, Cell Reports Medicine, and Xenotransplantation.